NCT07535632 2026-04-17
BEST
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
Clinical Trials
8 trialsNCT07506109 2026-04-07
A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT05427487 2026-03-25
Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours
ImmVirx Pty Ltd
Phase 1 Recruiting
NCT06497985 2026-03-19
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
Chipscreen Biosciences, Ltd.
Phase 3 Recruiting
NCT05171660 2026-02-17
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3 Active not recruiting
NCT07398326 2026-02-09
Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer
Shanghai Changzheng Hospital
Phase 2 Recruiting
NCT06356584 2025-06-26
Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT06794086 2025-05-13
SPARKLE-L
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3 Recruiting